Long-Term Reduction in {orange:Proximal Shunt Revisions}
A 9-patient case series peer-reviewed in {orange:Pediatric Neurosurgery} demonstrating a dramatic reduction in {orange:proximal shunt failures} following ReFlow implantation.

{orange:Overview}
In a case series peer-reviewed in Pediatric Neurosurgery, researchers followed 9 pediatric hydrocephalus patients who had experienced 14 proximal shunt failures in the two years prior to ReFlow implantation. Each patient received the ReFlow® Mini Flusher and began regular flushing as part of their shunt maintenance.
Follow-up was conducted over a 2–4 year period post-implantation, with the primary endpoint being the number of proximal shunt failures requiring revision surgery.
{orange:Key Findings}
Across all 9 patients over the 2–4 year follow-up period:
- 14 proximal failures occurred in the two years before ReFlow implantation
- Only 1 proximal failure occurred in the 2–4 years following ReFlow implantation
- Caregiver compliance with the maintenance flushing protocol averaged 94% at two years, demonstrating real-world feasibility of the protocol outside clinical settings.
- Represents a substantial reduction in revision-requiring events within this cohort
- No device-related adverse events reported during the follow-up window
{orange:Clinical Implications}
For a pediatric population where shunt failure within the first year can reach 40–50%, these early results suggest that routine, noninvasive flushing may meaningfully shift the trajectory of long-term shunt management.
While these findings are from a small cohort and further study is warranted, they support the hypothesis that proactive maintenance, rather than reactive revision, may improve outcomes for children living with hydrocephalus.
Vinzani et al. Pediatr Neurosurg 2023;58:136–141
Read the paperFrequently Asked Questions
Common questions about ReFlow® technology, our clinical evidence, and the condition it's designed to treat.
Hydrocephalus is a condition where cerebrospinal fluid (CSF) accumulates in the brain's ventricles, often requiring a shunt to manage. Left untreated, it can cause serious neurological damage.
The ReFlow® Mini Flusher is implanted in-line with a standard shunt system. A simple, deliberate press of the dome sends less than half a millilitre of fluid toward the ventricular catheter to clear blockages and restore CSF flow, without surgery.
Yes. The ReFlow® Mini Flusher is FDA 510(k) cleared and CE Marked. The broader ReFlow System has also received two FDA Breakthrough Device Designations (2021 and 2025).
Under the direction of the treating physician, flushing can be performed by a trained healthcare professional in-clinic, or by a trained caregiver or adult patient in a non-clinical setting.
Flushing frequency is determined by the treating physician based on individual patient needs. ReFlow is designed to support both on-demand clearing and routine maintenance flushing.
Yes. ReFlow has been evaluated across multiple published studies and clinical case series, with over 30 patients implanted across leading US neurosurgical centres with up to 6 years of follow-up.
Yes. The device is designed to support a broad patient population, from infants to older adults, and has been studied specifically in pediatric hydrocephalus cohorts.
No. The procedure to attach the ReFlow Mini Flusher does not significantly alter the shunt implant technique or add a significant amount of time.
The ReFlow System Mini and ReFlow Mini Flusher are currently available in the United States.
Clinicians, patients, and partners can reach our team directly via the Contact page. We're always happy to discuss ReFlow® and the science behind our platform.



